Marex Group’s Nuvectis Pharma NVCT Stock Holding History

Marex Group’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-15,000	Closed	-$112K	–	967
2025 Q2	$112K	Buy	+15,000	New	+$136K	﹤0.01%	560

Other funds holding NVCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $165M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Marex Group's NVCT Position: Q3 2025 in Review

Marex Group sold out of Nuvectis Pharma (NVCT) in Q3 2025, closing a stake of 15,000 shares — an estimated $112K sold.

Marex Group first reported a position in NVCT in Q2 2025 and held it in 1 quarter. The position peaked at $112K in Q2 2025. 53 funds tracked by Wall St. Rank hold NVCT as of Q3 2025.

Marex Group reported no remaining Nuvectis Pharma position as of Q3 2025 after selling out during the quarter.
Marex Group sold 15,000 Nuvectis Pharma shares in Q3 2025, an estimated $112K.
Marex Group first reported a position in Nuvectis Pharma in Q2 2025 and held it in 1 quarter.
Marex Group's Nuvectis Pharma position peaked at $112K in Q2 2025.
53 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2025.

Based on Marex Group's 13F filing for Q3 2025, filed 14 Nov 2025.